Literature DB >> 17999051

Candidate gene polymorphisms predicting individual sensitivity to opioids.

Shinya Kasai1, Masakazu Hayashida, Ichiro Sora, Kazutaka Ikeda.   

Abstract

Significant interindividual differences in opioid sensitivity can hamper effective pain treatment and increase the risk for substance abuse. Elucidation of the genetic mechanisms involved in the interindividual differences in opioid sensitivity would help establish personalized pain management. Studies using gene knockout mice have revealed that genes encoding some metabolic enzymes, opioid transporters, and opioid system signal transduction mediators may be candidate genes to predict appropriate kinds and doses of opioids for individuals. Recently, various databases on knockout mice, pharmacogenetics, and gene polymorphisms have been rapidly consolidated. Such information should aid in developing and improving the methods of predicting interindividual differences in opioid sensitivity. In the near future, it will be possible to predict the appropriate kinds and doses of opioids for individuals by analyzing genetic variations contributing to opioid sensitivity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17999051     DOI: 10.1007/s00210-007-0205-3

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  169 in total

1.  Augmented responses to morphine and cocaine in mice with a 12-lipoxygenase gene disruption.

Authors:  Carrie L Walters; Bao-Cheng Wang; Misty Godfrey; Duxin Sun; Colin D Funk; Julie A Blendy
Journal:  Psychopharmacology (Berl)       Date:  2003-07-04       Impact factor: 4.530

2.  Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G.

Authors:  Ying Zhang; Danxin Wang; Andrew D Johnson; Audrey C Papp; Wolfgang Sadée
Journal:  J Biol Chem       Date:  2005-07-26       Impact factor: 5.157

3.  Morphine-6-O-beta-D-glucuronide but not morphine-3-O-beta-D-glucuronide binds to mu-, delta- and kappa- specific opioid binding sites in cerebral membranes.

Authors:  S V Löser; J Meyer; S Freudenthaler; M Sattler; C Desel; I Meineke; U Gundert-Remy
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-07       Impact factor: 3.000

4.  Enhanced morphine analgesia in mice lacking beta-arrestin 2.

Authors:  L M Bohn; R J Lefkowitz; R R Gainetdinov; K Peppel; M G Caron; F T Lin
Journal:  Science       Date:  1999-12-24       Impact factor: 47.728

5.  The untranslated region of (mu)-opioid receptor mRNA contributes to reduced opioid sensitivity in CXBK mice.

Authors:  K Ikeda; T Kobayashi; T Ichikawa; T Kumanishi; H Niki; R Yano
Journal:  J Neurosci       Date:  2001-02-15       Impact factor: 6.167

6.  Primary structure and functional expression of a rat G-protein-coupled muscarinic potassium channel.

Authors:  Y Kubo; E Reuveny; P A Slesinger; Y N Jan; L Y Jan
Journal:  Nature       Date:  1993-08-26       Impact factor: 49.962

7.  Alterations in morphine-induced reward, locomotor activity, and thermoregulation in CREB-deficient mice.

Authors:  Carrie L Walters; Misty Godfrey; Xiao Li; Julie A Blendy
Journal:  Brain Res       Date:  2005-01-25       Impact factor: 3.252

8.  Morphine-6-glucuronide: analgesic effects and receptor binding profile in rats.

Authors:  F V Abbott; R M Palmour
Journal:  Life Sci       Date:  1988       Impact factor: 5.037

9.  The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine.

Authors:  Jörn Lötsch; Carsten Skarke; Sabine Grösch; Jutta Darimont; Helmut Schmidt; Gerd Geisslinger
Journal:  Pharmacogenetics       Date:  2002-01

10.  Identification of CYP3A4 and CYP2C8 as the major cytochrome P450 s responsible for morphine N-demethylation in human liver microsomes.

Authors:  D Projean; P-E Morin; T M Tu; J Ducharme
Journal:  Xenobiotica       Date:  2003-08       Impact factor: 1.908

View more
  6 in total

1.  Using the Phenogen website for 'in silico' analysis of morphine-induced analgesia: identifying candidate genes.

Authors:  Paula L Hoffman; Beth Bennett; Laura M Saba; Sanjiv V Bhave; Phyllis J Carosone-Link; Cheryl K Hornbaker; Katerina J Kechris; Robert W Williams; Boris Tabakoff
Journal:  Addict Biol       Date:  2010-11-04       Impact factor: 4.280

2.  Analgesia and central side-effects: two separate dimensions of morphine response.

Authors:  Joanne M Droney; Sophy K Gretton; Hiroe Sato; Joy R Ross; Ruth Branford; Kenneth I Welsh; William Cookson; Julia Riley
Journal:  Br J Clin Pharmacol       Date:  2013-05       Impact factor: 4.335

Review 3.  Medium Increased Risk for Central Sleep Apnea but Not Obstructive Sleep Apnea in Long-Term Opioid Users: A Systematic Review and Meta-Analysis.

Authors:  Marie-Lou Filiatrault; Jean-Marc Chauny; Raoul Daoust; Marie-Pier Roy; Ronald Denis; Gilles Lavigne
Journal:  J Clin Sleep Med       Date:  2016-04-15       Impact factor: 4.062

4.  Recent advances in the use of opioids for cancer pain.

Authors:  Joanne Droney; Julia Riley
Journal:  J Pain Res       Date:  2009-09-23       Impact factor: 3.133

5.  Prediction formulas for individual opioid analgesic requirements based on genetic polymorphism analyses.

Authors:  Kaori Yoshida; Daisuke Nishizawa; Takashi Ichinomiya; Tatsuya Ichinohe; Masakazu Hayashida; Ken-ichi Fukuda; Kazutaka Ikeda
Journal:  PLoS One       Date:  2015-01-23       Impact factor: 3.240

6.  Prospective observational pharmacogenetic study of side effects induced by intravenous morphine for postoperative analgesia.

Authors:  Li-Kuei Chen; Mao-Hsien Wang; Hong-Jyh Yang; Shou-Zen Fan; Shiou-Sheng Chen
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.